Gaffke G, Gebauer B, Gnauck M, Knollmann F D, Helmberger T, Ricke J, Oettle H, Felix R, Stroszczynski C
Klinik für Strahlenheilkunde und Poliklinik, Charité, Universitätsmedizin Berlin.
Rofo. 2005 Jan;177(1):77-83. doi: 10.1055/s-2004-813643.
To present first results of radiofrequency ablation of liver tumors using a new MR compatible applicator.
We performed 37 interventions in 20 patients (mean age 58.6 years) with primary intrahepatic malignancies or metastases: colorectal carcinoma n = 6, hepatocellular carcinoma n = 3, pancreatic carcinoma n = 4, sarcoma n = 2, cholangiocellular carcinoma n = 1, carcinoma of the tonsil n = 1, breast carcinoma n = 1, gastric carcinoma n = 1, and gastrointestinal stroma tumor n = 1. Interventions were performed under CT-guidance with CT fluoroscopy (n = 32) and under MR-guidance (n = 5) using fast T1-weighted sequences in breath-hold technique. RFA was performed with the RF-generator (150 W) under local anesthesia and sedation using MR compatible applicators (Starburst XL, Rita Medical Systems, USA) together with the appropriate Soft Tissue Introducer System. Intra-interventional control was performed with intrahepatically or intralesionally placed introducer system or applicator. MRI was performed with plain breath-triggered T2-weighted turbo spin echo sequences (TSE T2) with fat saturation.
All interventions were performed without major events. The mean diameter of induced coagulation was 4.0 (+/- 0.7) cm. Repositioning was necessary in 8 interventions (21 %) after detection of residual tumor on an intra-interventional MRI. After a mean follow-up of 6.5 (+/- 1.2) months, the local tumor control rate was 92 %.
MR-compatible RF applicators offer the opportunity for intra-interventional detection of residual tumor during RF ablations by use of sensitive MRI sequences. These procedures may lead to a higher confidence in tumour ablation and may reduce the number of re-interventions and local recurrences of intrahepatic tumors.
展示使用新型磁共振兼容施源器进行肝脏肿瘤射频消融的初步结果。
我们对20例(平均年龄58.6岁)原发性肝内恶性肿瘤或转移瘤患者进行了37次干预:结直肠癌6例,肝细胞癌3例,胰腺癌4例,肉瘤2例,胆管细胞癌1例,扁桃体癌1例,乳腺癌1例,胃癌1例,胃肠道间质瘤1例。干预在CT引导下采用CT透视(32例)以及在磁共振引导下(5例)进行,后者使用屏气技术的快速T1加权序列。在局部麻醉和镇静下,使用磁共振兼容施源器(美国Rita Medical Systems公司的Starburst XL)以及合适的软组织导入系统,通过射频发生器(150 W)进行射频消融。介入过程中通过肝内或瘤内放置的导入系统或施源器进行控制。使用脂肪饱和的呼吸触发T2加权快速自旋回波序列(TSE T2)进行磁共振成像。
所有干预均未发生重大事件。诱导凝固坏死的平均直径为4.0(±0.7)cm。介入过程中磁共振成像检测到残留肿瘤后,8次干预(21%)需要重新定位。平均随访6.5(±1.2)个月后,局部肿瘤控制率为92%。
磁共振兼容射频施源器通过使用敏感的磁共振序列,为射频消融过程中残留肿瘤的介入检测提供了机会。这些操作可能会提高对肿瘤消融的信心,并可能减少再次干预的次数和肝内肿瘤的局部复发。